Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.43 |
| ▸ | CSF1R | P07333 | 12/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28881229 | 0.83 | TGFBR1 (0.41) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 | |
| SCHEMBL16027990 | 0.82 | CSF1R (0.48) | CSF1RPDGFRAPDGFRBCYP2C9FLT3 | |
| SCHEMBL16028424 | 0.82 | SCN9A (0.43) | TGFBR1 | |
| SCHEMBL3947048 | 0.81 | TGFBR1 (0.53) | TGFBR1CSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL16028837 | 0.79 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL30891513 | 0.79 | TGFBR1 (0.43) | TGFBR1CSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL21584975 | 0.78 | CSF1R (0.48) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 | |
| SCHEMBL16061121 | 0.77 | ALDH1A1 (0.41) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 | |
| SCHEMBL22165803 | 0.77 | TGFBR1 (0.39) | TGFBR1CSF1RPDGFRAPDGFRBFLT3 | |
| SCHEMBL31740642 | 0.76 | TGFBR1 (0.42) | TGFBR1CSF1RPDGFRAPDGFRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193719-B2 | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140296252-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014145023-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296252-A1 | 1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, CSF1R, CSF3R | TGFBR1 985/4885CSF1R 2/4885PDGFRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.